Phylogenomics of phosphoinositide lipid kinases: perspectives on the evolution of second messenger signaling and drug discovery
© Brown and Auger; licensee BioMed Central Ltd. 2011
Received: 4 August 2010
Accepted: 5 January 2011
Published: 5 January 2011
Phosphoinositide lipid kinases (PIKs) generate specific phosphorylated variants of phosatidylinositols (PtdIns) that are critical for second messenger signaling and cellular membrane remodeling. Mammals have 19 PIK isoforms spread across three major families: the PtIns 3-kinases (PI3Ks), PtdIns 4-kinases (PI4Ks), and PtdIns-P (PIP) kinases (PIPKs). Other eukaryotes have fewer yet varying PIK complements. PIKs are also an important, emerging class of drug targets for many therapeutic areas including cancer, inflammatory and metabolic diseases and host-pathogen interactions. Here, we report the genomic occurrences and evolutionary relationships or phylogenomics of all three PIK families across major eukaryotic groups and suggest potential ramifications for drug discovery.
Our analyses reveal four core eukaryotic PIKs which are type III PIK4A and PIK4B, and at least one homolog each from PI3K (possibly PIK3C3 as the ancestor) and PIP5K families. We also applied evolutionary analyses to PIK disease ontology and drug discovery. Mutated PIK3CA are known to be oncogenic and several inhibitors are in anti-cancer clinical trials. We found conservation of activating mutations of PIK3CA in paralogous isoforms suggesting specific functional constraints on these residues. By mapping published compound inhibition data (IC50s) onto a phylogeny of PI3Ks, type II PI4Ks and distantly related, MTOR, ATM, ATR and PRKDC kinases, we also show that compound polypharmacology corresponds to kinase evolutionary relationships. Finally, we extended the rationale for drugs targeting PIKs of malarial Plasmodium falciparum, and the parasites, Leishmania sp. and Trypanosoma sp. by identifying those PIKs highly divergent from human homologs.
Our phylogenomic analysis of PIKs provides new insights into the evolution of second messenger signaling. We postulate two waves of PIK diversification, the first in metazoans with a subsequent expansion in cold-blooded vertebrates that was post-emergence of Deutrostomia\Chordata but prior to the appearance of mammals. Reconstruction of the evolutionary relationships among these lipid kinases also adds to our understanding of their roles in various diseases and assists in their development as potential drug targets.
PIKs can be broadly categorized into three major protein types: PtIns 3-kinases (PI3Ks), PtdIns 4-kinases (PI4Ks), and PtdIns-P (PIP) kinases (PIP5Ks and PIP4Ks). PI3Ks has eight known isoforms in mammals which are differentiated into three to four classes by amino acid sequence homology, regulator domains and activation cascades [2, 3]. Mammals have three Class Ia PI3Ks sharing homologous catalytic polypeptide subunits p110α (PIK3CA), p110β (PIK3CB) and p110δ (PIK3CB). (For clarity, HUGO gene names are in parenthesis and used throughout to refer to their protein products.) Class Ia PI3Ks are heterodimeric protein complexes consisting of the catalytic and regulatory subunits. Class Ia kinases are multi-domain proteins having, in order from the N-terminus, a binding domain for p85 regulatory proteins, a RAS binding domain (RBD) as well as C2, helical (PIK) and catalytic domains. The sole Class Ib PI3K, PIK3CG, has a distinctive p101 regulatory domain as well as homologous, RBD, C2, helical and p110γ catalytic domains. Class II PI3Ks lack either p85 or p101 regulatory domains yet have a p110 catalytic domain and the other domains. In humans, there are three Class II isoforms, PIK3C2α (PIK3C2A), PIK3C2β (PIK3C2B) and PIK3C2γ (PIK3CG). Class III PI3K is represented by a single isoform, PIK3C3 (also known from yeast studies as vacuolar protein-sorting defective 34 or Vps34), and is the least complex PI3K kinases having only C2, helical and catalytic domains.
There are two types of PI4Ks each comprised of two known paralogous isoforms in vertebrates. These are known as Type II, PI4KIIα (PI4K2A) and PI4KIIβ (PI4K2B), and Type III PI4KIIIα (PIK4CA) and PI4KIIIβ (PIK4CB) [4, 5]. PI4KIIIs share sequence homology with PI3K and together comprise the largest family of phosphoinositide lipid kinases. PI4KII isoforms do not share sequence homology with either PI4KIII or PI3K kinases. The third PIK family is the phosphatidylinositol-4-phosphate 5-kinases (PIP5K) or PIP kinases which lack primary sequence or structural homology to either PI3Ks or any type of PI4Ks . In mammals, there are three types of PIP kinases or PIPKs. Type I PIP5K occurs as three homologs known as PIP5K1-α (PIP5K1A), PIP5K1-β (PIP5K1B) and PIP5K1-γ (PIP5K1C). Type II phosphatidylinositol-4-phosphate 5-kinase also has three isoforms called PIP4K2-α (PIP4K2A), PIP4K2-β (PIP4K2B) and PIP4K2-γ (PIP4K2C). Both Type I and II PIPKs are homologs to yeast Mss4p. A third PIPK is PIKFYVE has been recently designated as PIP5K3 and includes yeast Fab1p.
PI3K-AKT-mTOR signaling is a central regulatory axis for many key cellular functions including cell cycle, protein synthesis and glucose metabolism. Thus it is not surprising that many diverse disease etiologies have been associated with dysfunctional PIKs including cancer, diabetes and heart disease . Phosphatidylinositol 3-kinase α peptide (PIK3CA) is highly mutated in colon, brain and gastric cancers where apparent gain-of-function mutations confer increased activity for this lipid kinase [8, 9]. Several small molecule inhibitors of PIK3CA are in anti-cancer clinical trials [10, 11]. The paralog PIK3C-γ or PIK3CG is broadly implicated in many diseases due to its role as a downstream signaling component of chemokine receptors that modulate inflammatory pathways . For example, PIK3CG has been suggested as a heart disease target because of its roles in atherosclerosis related inflammation  and pathogenesis of cardiac hypertrophy and heart failure . Recent studies also suggest that PI4KIIIs are essential host factors utilized by the hepatitis C virus (HCV) to remodel the intracellular matrix for virus replication and release [15, 16].
PtdIns and PIKs are evolutionary well conserved. In fact, inositol precursors are found in bacteria and archaea although phosphorylated derivatives are strictly eukaryotic . Homologs for all three PIKs groups (PI3K, PI4K, and PIPK) occur across major taxonomic clusters of eukaryotes although the number of isoforms is highly variable with greater complexity among metazoans, especially the vertebrates . Clearly, the emergence and diversification of PIKs second messenger signaling is a hallmark, and potential facilitator, of eukaryotic evolution. However, questions remain about the antiquity of the various PIK subfamilies and the timing of the radiation and divergence of these lipid kinases relative to the emergence of major taxonomic groups. This knowledge is potentially relevant to biomedical interests in PIKs such as in the interpretation and design of model organism studies, characterization of mutations and polymorphic variants and evaluation of potential polypharmacology . In addition, kinase inhibitors have been suggested as novel therapeutics against devastating eukaryotic parasitic diseases such as malaria, caused by the Apicomplexa protists, Plasmodium falciparum and P. vivax , as well as leishmaniasis and trypanosomiasis that result from infections of Leishmania sp., and Trypanosoma sp., respectively, both members of the Kinetoplastids . Here, we provide a comprehensive genomic survey and phylogenetic analyses of the major types of PIKs. We show the significance of these results in understanding the evolution of second messenger signaling as well as exploiting PIKs as drug targets for various therapeutic areas.
Phylogeny of PI3K and PI4KIII kinases
In this study, we focused on the phylogenetic analyses of the phosphoinositide lipid kinases from representative species across seven major taxonomic groups: the Mammalia, Vertebrata (specifically cold-blooded vertebrates), Chordata/Deutrostomia, Protosomatia (insects/arthropods), Pseudocoelomata (nematoda worms), Viridiplantae (green plants), Fungi as well as various protists with an emphasis on human eukaryotic parasitic groups Apicomplexa and Kinetoplastids. We retrieved amino acid sequences from GenBank NonRedundant (nr) and species-specific databases via BLASTP  searches using human PIK proteins as the initial queries (see Methods). As necessary, sequences from other species were used as queries to obtain further homologs. While all homologs were initially collected, representative species for each taxonomic major group were selected for phylogenetic analyses on the basis of sequence completeness which was not consistent across all genomes sequences. For example, mammalian kinases could be consistently represented by human (Homo sapiens), rat (Rattus norvegicus) and mouse (Mus musculus) sequences while Chordata/Deutrostomia were represented by an aggregate of one or more homologs from the genome sequences available for species of Deutrostomia (Strongylocentrotus purpuratus, sea urchin), Tunicata (Ciona intestinalis, tunicate) and/or Cephalochordata (Branchiostoma floridae, Florida lancelet or amphioxus). For each of the three major PIKs families, sequences were aligned, edited to the core conserved amino acids and phylogenetic analyses were performed.
The eight isoforms of the PI3K family have a specific hierarchy with PIK3C3 (phosphoinositide-3-kinase, class III) the most divergent relative to PIK3C2 (phosphoinositide-3-kinase, class II) and PIK3C (phosphoinositide-3-kinase, class I) proteins. PIK3C3 occurs in all major taxonomic groups and is the sole PI3K class protein encoded in the genomes of plants, fungi and Apicomplexan (Plasmodium sp.). However, Kinetoplastids species have a second PI3K which appears intermediate in homology to Class I and II kinases of metazoans.
PIK Classes Ia, Ib and II cluster together with high bootstrap/probability values and, within each class, the nodes clustering the various isoforms also have strong bootstrap and Bayesian posterior probability support. Class II kinases are specific to metazoans. Of the three isoforms, PIK3C2G (phosphoinositide-3-kinase, class 2, γ polypeptide) is the most divergent and appears common to all species. Nematodes and arthropods are not monophyletic, which is likely an artifact of tree reconstruction resulting from too few phylogenetically informative sites to resolve the evolutionary relationships among these invertebrate species. PIK3C2A (α polypeptide) and PIK3C2B (β polypepetide) are both vertebrate specific and form a strongly supported clade. Deutrostomia/Chordata species have a single PIK3C2 ortholog which, although not entirely well resolved in the overall PI3KC2 cluster, appears to be ancestral to both PIK3C2A and PIK3C2B suggesting the latter two proteins evolved from a gene duplication event in early cold-blooded vertebrates.
Similarly, Class I PI3Ks are mainly found in metazoans with a single isoform in invertebrates. Phylogenetic analysis shows two distinct subclusters of duplicated vertebrate sequences, one of PIK3CB and PIK3CD while the other is comprised of PIK3CA and PIK3CG. Each subcluster has a single ancestral ortholog gene which is found in all three species representing the Deutrostomia/Chordata. Therefore, at least two further gene duplications occurred after the emergence of true vertebrates, one lead to PIK3CB and PIK3CD while the other resulted in PIK3CA and PIK3CG.
Phylogeny of Class II PI4K kinases
Phylogeny of PIP5 kinases
The PIP5K family consists of three distantly related groups of proteins, PIP5K1 (phosphatidylinositol-4-phosphate 5-kinase, type I), PIP4K2 (phosphatidylinositol-5-phosphate 4-kinase, type II) and PIP5K3 (phosphatidylinositol-4-phosphate 5-kinase, type III) or PIKFYVE. In contrast to PI3K/PI4KIII and PI4KII kinases, the relative evolutionary relationships between these major subfamilies are poorly resolved. Although these proteins share recognizable sequence similarity, in comparison to PI3K/PI4KIII and PI4KII, fewer amino acids could be confidently aligned thus reducing the phylogenetic signal. Furthermore, most eukaryotes have multiple proteins with FYVE finger motifs that are not active kinases but rather kinase substrates . Therefore, we removed from our analysis any proteins with low kinase domain homology (Additional files 1 and 4).
Plants have multiple, duplicated enzymes which are most similar to PIP5K1 and PIP4K2 kinases although phylogenetic analyses could not confidently cluster plant kinases within either subtype. No PIP5K3 homologs were found in plants. Kinetoplastid species have lineage specific duplications of PIP5K1-like kinases as well as a single PIP5K3 kinase. In contrast, Apicomplexa have a single isoform that is most similar to PIP5K1 kinases. The major nodes connecting plant, yeast, metazoan, Kinetoplastid and Apicomplexa isoforms were not well supported by bootstrap or probability values, therefore no inference can be made about the relative order of evolutionary emergence of the major PIPK types.
Evolution of Second Messenger Signaling
Among the eight known PI3K family proteins, PIK3C3 is the most likely candidate ancestral kinase of this subfamily. Two pieces of evidence in our analysis support this hypothesis. First, single PIK3C3 orthologs are found in all eukaryotic groups . Second, phylogenetic analysis firmly establishes the early divergence of PIK3C3 from Class I and II PI3Ks. This assessment is congruent with the early pathway catalytic function of PIK3C3 in the generation of PtdIns-3-phosphate (PtdIns-3-P) from a PtdIns precursor. In addition, PIK3C3 has the simplest protein structure among all PI3K kinases insofar as it lacks the RAS binding domains of Class Ia, Ib and II PI3Ks as well as the p85/p110 regulatory domains of Class Ia PI3Ks. Although only the core PIK and catalytic domains were used for the construction of the PI3/4K phylogenetic tree, the branching order of the three PI3K Classes corresponds well with the general trend towards increasing kinase complexity in terms of the number of regulatory domains and the capability to phosphorylate more complex PtdIns derivatives.
With the exception of some Kinetoplastid sequences, Class I and II PI3Ks are metazoan specific proteins. Our phylogenomic analysis suggests an evolutionary trend where increasing organism complexity is associated with two major waves of PIK diversification (Figure 5). First, in early metazoans gene duplications lead to the emergence of Class I and II PIKs as well as PIP5K1 and PIP4K2 families. This is evident from the wider repertoire of PIK isoforms in invertebrates relative to plants, fungi and protists. The second gene expansion occurred in early, true vertebrates. For most PIKs, a series of gene duplications occurred in cold-blooded vertebrates after their divergence from early urochordates but before the emergence of mammals. Representative species of the Deutrostomia (Strongylocentrotus purpuratus), Tunicata (Ciona intestinalis) and Cephalochordata (Branchiostoma floridae) mostly have the same PIK complement as arthropods and other invertebrates. Possible exceptions are the Class Ia and Class Ib PIKs where a single corresponding ortholog for each subclass can be found in the Deutrostomia/Chordata species. Thus the initial diversification of Class I PI3Ks likely occurred in the early deutrostome lineage followed by two additional gene duplications in vertebrates resulting in contemporary complement of four Class I PIKs throughout cold-blooded vertebrates and mammals.
Many different genes spanning wide functional categories have undergone major gene duplications in vertebrates and mammals. However, given the crucial role of second messenger signaling, it is tempting to speculate that increasing multi-cellular complexity was accompanied and, perhaps facilitated, by the evolution of more diverse and specialized PIKs signaling cascades.
Evolutionary Context for Cancer Mutations
The gene for phosphoinositide-3-kinase α peptide (PIK3CA) is highly mutated in colon, brain and gastric cancers where apparent gain-of-function mutations confer increased activity for this lipid kinase [8, 9]. Our phylogenetic analysis shows that PIK3CA is most closely related to other class Ia and Ib kinases, PI3KC-ß (PIK3CB), PI3KC-δ (PIK3CD), and PI3KC-γ (PIK3CG) (Figure 2). Thus further knowledge about tumor-related mutations in PIK3CA might be gained by comparing those variants to orthologs in other species as well as paralogs of related kinases.
Gymnopoulos et al.  measured the oncogenic potential of the 15 most common PIK3CA mutations found in tumors by introducing retroviral expression vectors with each of the variants into avian cells and measuring their individual efficiencies for tumorigenic transformation. Their functional assays confirmed that the mutation H1047R strongly conferred oncogenic potency while moderate and weak potency was induced by the variants H1047L and H1047Y, respectively. Interestingly, PIK3CA H1047R mutation aligns with an arginine found in normal human PIK3CG while H1047L corresponds to leucine in wild-type PIK3CB and PIK3CD (Figure 6). H1047Y is rarely found in tumors, appears to convey much weaker oncogenic potency than the other two mutations and is not conserved in any Class I PI3K paralog. The correspondence of certain cancer mutations in PIK3CA to those found in normal paralogs suggests that selection pressures in the tumor might limit the range of acceptable amino acid changes. One might speculate that these constrained amino acid changes in a mutated PIK3CA protein could lead to convergence in function, protein interactions or regulation with those of PIK3CB, PIK3CG or PIK3CD. Gymnopoulos and co-workers mapped H1047R/L mutations onto a structural model of PIK3CA which suggested that these changes are located near the hinge region of the activation loop and could serve to increase catalytic activity . Given the importance of mutated kinases in tumor cell viability and their increased exploitation as cancer drug targets, better insights into delineating between passenger and driver mutations might be gained through broader sequence comparisons across different species as well as related protein family members [29, 30].
PIK Inhibitor Polypharmacology
Knight et al. reported inhibition data for compounds screened across the entire PIK3C family as well as several more distantly related PI3K-like kinases such as ATM (ataxia telangiectasia mutated), ATR (ataxia telangiectasia and Rad3 related), PRKDC (protein kinase, DNA-activated) and MTOR (mechanistic target of rapamycin) . Their study did not include a phylogenetic or comparative sequence analyses but rather used separate principal component analysis (PCA) plots to compare the statistical space of target similarity versus compound-target inhibition values. More recently, the same group published in Apsel et al. the results of several dual inhibitors of both tyrosine and PI3K and PIK4A kinases . Compounds were assayed for inhibition against all Class Ia and Ib PI3Ks, MTOR, PRKDC and PIK4A as well as several tyrosine kinases although not all screening panels had a complete kinase set.
The published compound data has some limitations insofar that not all possible lipid kinase homologs were assayed. For example, Apsel et al.  do not report any compound assay data for PIK3C2 or PIK3C3 kinases. However, there is an overall trend for compounds with broad Class I PI3K spectrum to inhibit other PIKs as well as more distantly related kinases. Conversely, compounds with high potency to a subset of Class I PI3Ks tend to be more specific. Selective polypharmacology of PIKs might be an important goal for certain disease indications. Foukas et al. suggest that Class Ia PI3Ks have functional redundancy in cancer cells, so inhibition of multiple isoforms might be desirable . Conversely, selective inhibition of a particular PI4KIII isoform might be necessary for developing a well-tolerated anti-hepatitis C viral therapy [15, 16]. Further molecular modeling and testing with additional compound chemotypes might help illuminate the particular binding interactions that are involved in compound specificities.
PIKs as Anti-parasite Drug Targets
Some of the world's most important infectious diseases are caused by eukaryotic single-cell parasites. For example, approximately 243 million cases of malaria and 863,000 attributed deaths were reported globally in 2009 . The causative agents of malaria are the Apicomplexa parasites of which Plasmodmium falciparum followed by P. vivax are the two most important infectious agents. Globally, millions are afflicted by the diseases Leishmaniasis (kala-azar disease) and trypanosomiasis (Chagas disease and sleeping sickness) which result from infections of two genera of Kinetoplastids, Leishmania sp., and Trypanosoma sp., respectively . New drugs against these parasites are urgently required because of toxicities of existing therapies, the lack of pediatric formulations and the emergence of drug-resistant strains. The need for novel drugs is particularly acute for malaria where there have been increasing reports of P. falciparum strains with reduced clinical response to the latest class of artemisinin-containing drug combinations [36, 37].
As shown in our phylogenetic trees, parasite kinases are divergent from human host homologs suggesting potential scope for developing compounds with specificity to bind Leishmania, Trypanosoma or Plasmodium PIKs. However, Kinetoplastids and Apicomplexa are evolutionary distinct groups. The Apicomplexa, including Plasmodium sp., have been proposed to evolve from an ancestor that acquired a secondary plastid through endosymbiosis with a photosynthetic alga . In contrast, comparative genomic analyses of Trypanosoma cruzi, T. brucei and Leishmania major could not find significant evidence supporting similar plastid invasion into those genomes . Our findings of Type II PIK4 kinases being present in plants and Apicomplexa yet absent in Kinetoplastids, additional PI3K genes in Kinetoplastids and the overall non-clustering of these groups in our phylogenetic trees supports the varied evolutionary history of these protists. As such, differential development of kinase inhibitors for the treatment of malaria, leishmaniasis and trypanosomiasis might need to be considered. Malarial genes of putative plastid origins have been suggested to be potential drug targets because of their divergence from human homologs . In our analysis, the Type III PIK4CB and Type II PIK4B proteins of Plasmodium sp. cluster with plant orthologs with significant posterior probabilities and high bootstrap values suggesting a plant or cyanobacteria origin for those kinases. Understanding the evolutionary relationships of Trypanosoma, Leishmania and Plasmodium PIKs relative to each other and their human host will further facilitate both drug target selection and the design of counter-screen assays.
Phylogenomic analyses of PIKs show the progressive complexity of second messenger signaling from unicellular eukaryotes through metazoans and, finally, vertebrates. Furthermore, an evolutionary perspective is a potentially useful framework for characterizing PIKs as drug targets in cancer and parasitic diseases as well as providing insights into the polypharmacology of this important group of kinases.
We reconstructed the evolutionary relationships of three major lipid kinase families, PI3K/PI4KIII, PI4KI and PIP kinases, from representative species across seven major taxonomic groups Mammalia, Vertebrata (specifically cold-blooded vertebrates), Deutrostomia/Chordata, Protosomatia (insects/arthropods), Pseudocoelomata (nematoda worms), Viridiplantae (green plants), Fungi (yeasts and other fungi), and human eukaryotic parasitic groups Apicomplexa and Kinetoplastids. Protein (amino acid) sequences were retrieved from GenBank NonRedundant (nr) and species-specific databases via BLASTP  (default settings) searches using human PIK proteins as the initial queries. As necessary, sequences from other species or additional paralogs were used to obtain a full set of homologs with a cut-off of E-value ≤ 1.0e-10. Initially, large multiple sequence alignments were constructed for all available homologs for each of the three PIK families. Subsequently, representative species were selected on the basis of sequence completeness. For some of the major taxonomic groups, the genome sequence quality was inconsistent, so multiple species were used in each of PIK phylogenetics. For example, mammalian kinases could be consistently represented by human (Homo sapiens), rat (Rattus norvegicus) and mouse (Mus musculus) sequences while Deutrostomia/Chordata were represented by an aggregate of one or more homologs from the genome sequences available for species of Deutrostomia (Strongylocentrotus purpuratus, sea urchin), Tunicata (Ciona intestinalis, tunicate) and/or Cephalochordata (Branchiostoma floridae, Florida lancelet).
Initial multiple sequence alignments were performed using the program CLUSTALW v1.83  with default settings and subsequently, refined manually using the program SEQLAB of the GCG Wisconsin Package v11.0 software package (Accelrys, San Diego, CA, USA). We removed regions with residues that could not be unambiguously aligned or that contained insertions which resulted in edited alignments of the kinase families (length in amino acids or aa) PI3K/PI4KIII (236 aa), PIK4KII (269 aa), PIP (182 aa) and human PIK kinase homologs (133 aa). These multiple sequence alignments used in phylogenetic tree reconstructions in Figure 2, 3, 4 and 7 are included as Additional files 1, 2, 3, 4, 5.
We constructed phylogenetic trees using distance neighbor-joining (NJ) and Bayesian posterior probabilities (BP). NJ trees were based on pair wise distances between amino acid sequences using the programs NEIGHBOR and PROTDIST (Dayhoff option) of the PHYLIP 3.6 package . The programs SEQBOOT and CONSENSE were used to estimate the confidence limits of branching points from 1000 bootstrap replications. BP trees were constructed using the software MrBayes v3.0B4 [43, 44]. Bayesian analysis used the mixed model of sequence evolution with random starting trees. Markov chains were run for 106 generations, burn-in values were set for 104 generations, and trees sampled every 100 generations. All trees were visualized using the program TREEVIEW v1.6.6 .
PIK3CA mutations used to generate the composite cancer mutant human PI3KCA sequence in Figure 6 were obtained from Samuels et al.  and the Sanger COSMIC database . The IC50s shown in Figure 7, were obtained from published and supplementary materials provided by Knight et al.  and Apsel et al. . For the later study, we selected to use those compounds with PI3K inhibition IC50s which had been either shown in Figure 2a and/or were in supplementary material with determined PI4KA IC50s of 1.0 μM or better potencies.
We thank Julie Huxley-Jones, Christopher Moore and Philippe Sanseau for their comments on this manuscript. This research was support by Computational Biology, Quantitative Sciences, Medicine Discovery and Development, GlaxoSmithKline.
- Fruman DA, Meyers RE, Cantley LC: Phosphoinositide kinases. Annu Rev Biochem. 1998, 67: 481-507. 10.1146/annurev.biochem.67.1.481.View ArticlePubMedGoogle Scholar
- Engelman JA, Luo J, Cantley LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006, 7: 606-619. 10.1038/nrg1879.View ArticlePubMedGoogle Scholar
- Vanhaesebroeck B, Leevers SJ, Panayotou G, Waterfield MD: Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem Sci. 1997, 22: 267-272. 10.1016/S0968-0004(97)01061-X.View ArticlePubMedGoogle Scholar
- Gehrmann T, Heilmeyer LM: Phosphatidylinositol 4-kinases. Eur J Biochem. 1998, 253: 357-370. 10.1046/j.1432-1327.1998.2530357.x.View ArticlePubMedGoogle Scholar
- Balla A, Balla T: Phosphatidylinositol 4-kinases: old enzymes with emerging functions. Trends Cell Biol. 2006, 16: 351-361. 10.1016/j.tcb.2006.05.003.View ArticlePubMedGoogle Scholar
- Oude Weernink PA, Schmidt M, Jakobs KH: Regulation and cellular roles of phosphoinositide 5-kinases. Eur J Pharmacol. 2004, 500: 87-99. 10.1016/j.ejphar.2004.07.014.View ArticlePubMedGoogle Scholar
- Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD: Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol. 2001, 17: 615-675. 10.1146/annurev.cellbio.17.1.615.View ArticlePubMedGoogle Scholar
- Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al: High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004, 304: 554-10.1126/science.1096502.View ArticlePubMedGoogle Scholar
- Ikenoue T, Kanai F, Hikiba Y, Obata T, Tanaka Y, Imamura J, et al: Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res. 2005, 65: 4562-4567. 10.1158/0008-5472.CAN-04-4114.View ArticlePubMedGoogle Scholar
- Workman P, Clarke PA, Raynaud FI, van Montfort RL: Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res. 2010, 70: 2146-2157. 10.1158/0008-5472.CAN-09-4355.View ArticlePubMedPubMed CentralGoogle Scholar
- Engelman JA: Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009, 9: 550-562. 10.1038/nrc2664.View ArticlePubMedGoogle Scholar
- Ruckle T, Schwarz MK, Rommel C: PI3Kgamma inhibition: towards an 'aspirin of the 21st century'?. Nat Rev Drug Discov. 2006, 5: 903-918. 10.1038/nrd2145.View ArticlePubMedGoogle Scholar
- Fougerat A, Gayral S, Malet N, Briand-Mesange F, Breton-Douillon M, Laffargue M: Phosphoinositide 3-kinases and their role in inflammation: potential clinical targets in atherosclerosis?. Clin Sci (Lond). 2009, 116: 791-804. 10.1042/CS20080549.View ArticleGoogle Scholar
- Patrucco E, Notte A, Barberis L, Selvetella G, Maffei A, Brancaccio M, et al: PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell. 2004, 118: 375-387. 10.1016/j.cell.2004.07.017.View ArticlePubMedGoogle Scholar
- Tai AW, Benita Y, Peng LF, Kim SS, Sakamoto N, Xavier RJ, et al: A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host Microbe. 2009, 5: 298-307. 10.1016/j.chom.2009.02.001.View ArticlePubMedPubMed CentralGoogle Scholar
- Hsu NY, Ilnytska O, Belov G, Santiana M, Chen YH, Takvorian PM, et al: Viral reorganization of the secretory pathway generates distinct organelles for RNA replication. Cell. 2010, 141: 799-811. 10.1016/j.cell.2010.03.050.View ArticlePubMedPubMed CentralGoogle Scholar
- Michell RH: Inositol derivatives: evolution and functions. Nat Rev Mol Cell Biol. 2008, 9: 151-161. 10.1038/nrm2334.View ArticlePubMedGoogle Scholar
- Lecompte O, Poch O, Laporte J: PtdIns5P regulation through evolution: roles in membrane trafficking?. Trends Biochem Sci. 2008, 33: 453-460. 10.1016/j.tibs.2008.07.002.View ArticlePubMedGoogle Scholar
- Brown JR, Koretke KK, Birkeland ML, Sanseau P, Patrick DR: Evolutionary relationships of Aurora kinases: implications for model organism studies and the development of anti-cancer drugs. BMC Evol Biol. 2004, 4: 39-10.1186/1471-2148-4-39.View ArticlePubMedPubMed CentralGoogle Scholar
- Leroy D, Doerig C: Drugging the Plasmodium kinome: the benefits of academia-industry synergy. Trends Pharmacol Sci. 2008, 29: 241-249. 10.1016/j.tips.2008.02.005.View ArticlePubMedGoogle Scholar
- Bahia D, Oliveira LM, Lima FM, Oliveira P, Silveira JF, Mortara RA, et al: The TryPIKinome of five human pathogenic trypanosomatids: Trypanosoma brucei, Trypanosoma cruzi, Leishmania major, Leishmania braziliensis and Leishmania infantum--new tools for designing specific inhibitors. Biochem Biophys Res Commun. 2009, 390: 963-970. 10.1016/j.bbrc.2009.10.086.View ArticlePubMedGoogle Scholar
- Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, et al: Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997, 25: 3389-3402. 10.1093/nar/25.17.3389.View ArticlePubMedPubMed CentralGoogle Scholar
- Baldauf SL, Palmer JD: Animals and fungi are each other's closest relatives: congruent evidence from multiple proteins. Proc Natl Acad Sci USA. 1993, 90: 11558-11562. 10.1073/pnas.90.24.11558.View ArticlePubMedPubMed CentralGoogle Scholar
- McFadden GI: Mergers and acquisitions: malaria and the great chloroplast heist. Genome Biol. 2000, 1: REVIEWS1026-10.1186/gb-2000-1-4-reviews1026.View ArticlePubMedPubMed CentralGoogle Scholar
- Banerjee S, Basu S, Sarkar S: Comparative genomics reveals selective distribution and domain organization of FYVE and PX domain proteins across eukaryotic lineages. BMC Genomics. 2010, 11: 83-10.1186/1471-2164-11-83.View ArticlePubMedPubMed CentralGoogle Scholar
- Huang J, Mullapudi N, Sicheritz-Ponten T, Kissinger JC: A first glimpse into the pattern and scale of gene transfer in Apicomplexa. Int J Parasitol. 2004, 34: 265-274. 10.1016/j.ijpara.2003.11.025.View ArticlePubMedGoogle Scholar
- Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, et al: The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer. 2004, 91: 355-358.PubMedPubMed CentralGoogle Scholar
- Gymnopoulos M, Elsliger MA, Vogt PK: Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci USA. 2007, 104: 5569-5574. 10.1073/pnas.0701005104.View ArticlePubMedPubMed CentralGoogle Scholar
- Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, et al: Patterns of somatic mutation in human cancer genomes. Nature. 2007, 446: 153-158. 10.1038/nature05610.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhang Y, Italia MJ, Auger KR, Halsey WS, Van Horn SF, Sathe GM, et al: Molecular evolutionary analysis of cancer cell lines. Mol Cancer Ther. 2010, 9: 279-291. 10.1158/1535-7163.MCT-09-0508.View ArticlePubMedGoogle Scholar
- Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, et al: A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006, 125: 733-747. 10.1016/j.cell.2006.03.035.View ArticlePubMedPubMed CentralGoogle Scholar
- Apsel B, Blair JA, Gonzalez B, Nazif TM, Feldman ME, Aizenstein B, et al: Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008, 4: 691-699. 10.1038/nchembio.117.View ArticlePubMedPubMed CentralGoogle Scholar
- Foukas LC, Berenjeno IM, Gray A, Khwaja A, Vanhaesebroeck B: Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc Natl Acad Sci USA. 2010, 107: 11381-11386. 10.1073/pnas.0906461107.View ArticlePubMedPubMed CentralGoogle Scholar
- W.H.O. World malaria report. 2009, [http://www.who.int/malaria/world_malaria_report_2009/en/index.html]
- Dujardin JC, Gonzalez-Pacanowska D, Croft SL, Olesen OF, Spath GF: Collaborative actions in anti-trypanosomatid chemotherapy with partners from disease endemic areas. Trends Parasitol. 2010, 26: 395-403. 10.1016/j.pt.2010.04.012.View ArticlePubMedGoogle Scholar
- Andriantsoanirina V, Ratsimbasoa A, Bouchier C, Jahevitra M, Rabearimanana S, Radrianjafy R, et al: Plasmodium falciparum drug resistance in Madagascar: facing the spread of unusual pfdhfr and pfmdr-1 haplotypes and the decrease of dihydroartemisinin susceptibility. Antimicrob Agents Chemother. 2009, 53: 4588-4597. 10.1128/AAC.00610-09.View ArticlePubMedPubMed CentralGoogle Scholar
- Carrara VI, Zwang J, Ashley EA, Price RN, Stepniewska K, Barends M, et al: Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS ONE. 2009, 4: e4551-10.1371/journal.pone.0004551.View ArticlePubMedPubMed CentralGoogle Scholar
- Gamo FJ, Sanz LM, Vidal J, de CC, Alvarez E, Lavandera JL, et al: Thousands of chemical starting points for antimalarial lead identification. Nature. 2010, 465: 305-310. 10.1038/nature09107.View ArticlePubMedGoogle Scholar
- El-Sayed NM, Myler PJ, Blandin G, Berriman M, Crabtree J, Aggarwal G, et al: Comparative genomics of trypanosomatid parasitic protozoa. Science. 2005, 309: 404-409. 10.1126/science.1112181.View ArticlePubMedGoogle Scholar
- McFadden GI, Roos DS: Apicomplexan plastids as drug targets. Trends Microbiol. 1999, 7: 328-333. 10.1016/S0966-842X(99)01547-4.View ArticlePubMedGoogle Scholar
- Thompson JD, Higgins DG, Gibson TJ: CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994, 22: 4673-4680. 10.1093/nar/22.22.4673.View ArticlePubMedPubMed CentralGoogle Scholar
- Felsentein J: PHYLIP (Phylogenetic Inference Package). [3.6]. 2000, Seattle, Department of Genetics, University of Washington, [http://evolution.genetics.washington.edu/phylip.html]Google Scholar
- Huelsenbeck JP, Ronquist F: MRBAYES: Bayesian inference of phylogenetic trees. Bioinformatics. 2001, 17: 754-755. 10.1093/bioinformatics/17.8.754.View ArticlePubMedGoogle Scholar
- Ronquist F, Huelsenbeck JP: MrBayes 3: Bayesian phylogenetic inference under mixed models. Bioinformatics. 2003, 19: 1572-1574. 10.1093/bioinformatics/btg180.View ArticlePubMedGoogle Scholar
- Page RD: TreeView: an application to display phylogenetic trees on personal computers. Comput Appl Biosci. 1996, 12: 357-358.PubMedGoogle Scholar
- Maddison DR, Schulz K-S: The Tree of Life Web Project. 2007, [http://tolweb.org]Google Scholar
- Walker EH, Perisic O, Ried C, Stephens L, Williams RL: Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature. 1999, 402: 313-320. 10.1038/46319.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.